End-of-life care in oxygen-dependent ILD compared with lung cancer: A national population-based study

Thorax

Volumn 71, Issue 6, 2016, Pages 510-516

  Ahmadi, Zainab ^a   Wysham, Nicholas G ^b   Lundström, Staffan ^c   Janson, Christer ^d   Currow, David C ^e   Ekström, Magnus ^a,e  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c Stockholms Sjukhem Foundation   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

OXYGEN;

AGED; ANXIETY; ARTICLE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DYSPNEA; FEMALE; FIBROSING ALVEOLITIS; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OXYGEN THERAPY; PAIN; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; SURVIVAL TIME; SWEDEN; SYMPTOM; TERMINAL CARE; COMPARATIVE STUDY; EPIDEMIOLOGY; HEALTH CARE DELIVERY; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MORTALITY; PAIN MEASUREMENT; PALLIATIVE THERAPY; PROSPECTIVE STUDY; REGISTER;

AGED; ANXIETY; DYSPNEA; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; OXYGEN INHALATION THERAPY; PAIN MEASUREMENT; PALLIATIVE CARE; PROSPECTIVE STUDIES; REGISTRIES; SWEDEN; TERMINAL CARE;

EID: 84959170093     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2015-207439     Document Type: Article

References (37)

1. Demedts M, Wells AU, Antó JM, et al. Interstitial lung diseases: An epidemiological overview. Eur Respir J Suppl 2001; 32: 2s-16s.
2. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: Incidence, prevalence, and survival, 2001-11. Lancet Respir Med 2014; 2: 566-72.
3. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-92.
4. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-82.
5. Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011; 140: 221-9.
6. Ström K, Boman G. Long-term oxygen therapy in parenchymal lung diseases: An analysis of survival. The Swedish Society of Chest Medicine. Eur Respir J 1993; 6: 1264-70.
7. Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: Evidence of founder effect among multiplex families in Finland. Thorax 2002; 57: 338-42.
8. Lindell KO, Liang Z, Hoffman LA, et al. Palliative care and location of death in decedents with idiopathic pulmonary fibrosis. Chest 2015; 147: 423-9.
9. Bajwah S, Higginson IJ, Ross JR, et al. Specialist palliative care is more than drugs: A retrospective study of ILD patients. Lung 2012; 190: 215-20.
10. Irwin KE, Greer JA, Khatib J, et al. Early palliative care and metastatic non-small cell lung cancer: Potential mechanisms of prolonged survival. Chron Respir Dis 2013; 10: 35-47.
11. Gore JM, Brophy CJ, Greenstone MA. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax 2000; 55: 1000-6.
12. Habraken JM, ter Riet G, Gore JM, et al. Health-related quality of life in end-stage COPD and lung cancer patients. J Pain Symptom Manage 2009; 37: 973-81.
13. Steinhauser KE, Arnold RM, Olsen MK, et al. Comparing three life-limiting diseases: Does diagnosis matter or is sick, sick? J Pain Symptom Manage 2011; 42: 331-41.
14. Bajwah S, Ross JR, Peacock JL, et al. Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: A systematic review of the literature. Thorax 2013; 68: 867-79.
15. Bajwah S, Koffman J, Higginson IJ, et al. 'I wish I knew more ⋯' the end-of-life planning and information needs for end-stage fibrotic interstitial lung disease: Views of patients, carers and health professionals. BMJ Support Palliat Care 2013; 3: 84-90.
16. Bajwah S, Higginson IJ, Ross JR, et al. The palliative care needs for fibrotic interstitial lung disease: A qualitative study of patients, informal caregivers and health professionals. Palliat Med 2013; 27: 869-76.
17. Gustafson T, Dahlman-Höglund A, Nilsson K, et al. Occupational exposure and severe pulmonary fibrosis. Respir Med 2007; 101: 2207-12.
18. Ström K, Boe J. A national register for long-term oxygen therapy in chronic hypoxia: Preliminary results. Eur Respir J 1988; 1: 952-8.
19. Swedish National Register for Respiratory Failure (Swedevox). Annual report. 2014. http: //www.ucr.uu.se/swedevox/ (accessed 9 Oct 2015)
20. Ekström MP, Bornefalk-Hermansson A, Abernethy AP, et al. Safety of benzodiazepines and opioids in very severe respiratory disease: National prospective study. BMJ 2014; 348: G445.
21. Ekström MP, Hermansson AB, Ström KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 715-20.
22. Lundström S, Axelsson B, Heedman PA, et al. Developing a national quality register in end-of-life care: The Swedish experience. Palliat Med 2012; 26: 313-21.
23. Emilsson L, Lindahl B, Köster M, et al. Review of 103 Swedish Healthcare Quality Registries. J Intern Med 2015; 277: 94-136.
24. The Swedish Register of Palliative Care. http: //www.palliativ.se Annual report. 2013. http: //palliativ.se/wp-content/uploads/2014/03/SvenskaPalliatvregistret2014.pdf (accessed 1 Sep 2014).
25. Martinsson L, Heedman PA, Lundström S, et al. Validation study of an end-of-life questionnaire from the Swedish Register of Palliative Care. Acta Oncol 2011; 50: 642-7.
26. Fromme EK, Eilers KM, Mori M, et al. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 2004; 22: 3485-90.
27. Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using The National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. Lancet Oncol 2006; 7: 903-9.
28. Rocker G, Young J, Donahue M, et al. Perspectives of patients, family caregivers and physicians about the use of opioids for refractory dyspnea in advanced chronic obstructive pulmonary disease. CMAJ 2012; 184: E497-504.
29. Young J, Donahue M, Farquhar M, et al. Using opioids to treat dyspnea in advanced COPD: Attitudes and experiences of family physicians and respiratory therapists. Can Fam Physician 2012; 58: E401-7.
30. Currow DC, Abernethy AP. Therapeutic nihilism: The next hurdle in improving the treatment of breathlessness. Curr Opin Support Palliat Care 2011; 5: 69-70.
31. Moens K, Higginson IJ, Harding R, EURO IMPACT. Are there differences in the prevalence of palliative care-related problems in people living with advanced cancer and eight non-cancer conditions? A systematic review. J Pain Symptom Manag 2014; 48: 660-77.
32. Ahmadi Z, Lundström S, Janson C, et al. End-of-life care in oxygen-dependent COPD compared to cancer: A national population-based study. Eur Respir J 2015; 46: 1190-3.
33. Higginson IJ, Bausewein C, Reilly CC, et al. An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: A randomised controlled trial. Lancet Respir Med 2014; 2: 979-87.
34. Simon ST, Altfelder N, Alt-Epping B, et al. Is breathlessness what the professional says it is? Analysis of patient and professionals' assessments from a German nationwide register. Support Care Cancer 2014; 22: 1825-32.
35. NICE. IPF Quality Standards, section on pallitive care. https: //www.nice.org.uk/ guidance/qs79/chapter/Quality-statement-5-Palliative-care (accessed 3 Sep 2015).
36. Bajwah S, Ross JR, Wells AU, et al. Palliative care for patients with advanced fibrotic lung disease: A randomised controlled phase II and feasibility trial of a community case conference intervention. Thorax 2015; 70: 830-9.
37. Donovan KA, Jacobsen PB. Progress in the implementation of NCCN guidelines for distress management by member institutions. J Natl Compr Canc Netw 2013; 11: 223-6.